Accordingly, modulation of NK and T cell function through CD94/NKG2x receptors is of therapeutic interest; NKG2A has been proposed as a possible therapeutically relevant immune checkpoint, and anti-NKG2A monoclonal antibodies alone or in combination promote anti-tumor immunity in mouse models and Phase II clinical trials15–17. The gene discussed is KLRC1; the disease is neoplasm.